AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05936593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condylar Stabilizing (CS) insert
Description: During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
Study NCT05881486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: 8 mg Ondansetron+100 ml normal saline
Study NCT05881486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Description: 150 mg fosaprepitant +100 ml normal saline
Study NCT04850924 — intervention group
Intervention type: OTHER
Intervention: evaluation psychological trauma
Description: 9 classes of symptoms to be evaluated
Study NCT05936593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate Retaining (CR) insert
Description: During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
Study NCT04910386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab plus Gemcitabine&Cisplatin
Description: Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision
Study NCT04910386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine&Cisplatin
Description: The standard of care for the patients with unresectable/metastatic biliary tract cancer
Study NCT04875468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraCem self-adhesive resin cement
Description: MDP, calcium and fluoride releasing cement for dental zirconia crowns
Study NCT04875468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multilink adhesive resin cement
Description: (non MDP, non-calcium and fluoride releasing cement)
Study NCT05993988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Muscle relaxing Technique
Study NCT05587179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: recovery position
Description: A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
Study NCT05587179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recovery position
Description: A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
Study NCT04760860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin Hydrochloride
Description: In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.
Study NCT04760860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
Study NCT04916977 — intervention group
Intervention type: OTHER
Intervention: FD patients
Description: Patients with Fabry disease diagnosis
Study NCT03851627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: 1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
Study NCT03851627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Arm
Study NCT04920084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant based meals
Description: For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
Study NCT05752097 — intervention group
Intervention type: DEVICE
Intervention: [18F]AlF-NOTA-FAPI-04 PET/CT examination
Description: The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.
Study NCT05752097 — intervention group
Intervention type: PROCEDURE
Intervention: Renal puncture biopsy
Description: The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
Study NCT05088759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert
Description: The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
Study NCT01802541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diacylglycerol oil
Study NCT04403789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Time
Description: Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
Study NCT04403789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Group Exercise
Description: The intervention group will receive 2-hours of exercise sessions per week under the supervision of a certified trainer in the gym workplace. The intervention duration is 12 weeks.
Study NCT05493969 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dolutegravir 50 MG plus lamivudine 300 MG； Dolutegravir/lamivudine (50 MG/300 MG)
Description: Subjects will discontinue their TDF + 3TC/FTC-based regimen and will switch to DTG+3TC or fixed dose combination DTG/3TC.
Study NCT01255501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0701
Study NCT01255501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04919057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GelPOINT®
Description: The patient is laid in the exaggerated lithotomy and 15 degree Trendelenburg position. An incision is made between both ischial tuberosities. Perineal dissection is performed till the apex of the prostate is seen. Subcutaneous tissue laying under the incision borders is dissected deeply over the superficial perineal fascia to place the GelPOINT®.Once the robotic system is docked, dissection of prostate is started.
Study NCT01802541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: triacylglycerol oil
Study NCT05560152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqihuayu Decotion
Description: Per os, twice a day, for 7 days.
Study NCT05522296 — intervention group
Intervention type: DRUG
Intervention: Mpox Vaccine
Description: Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)
Study NCT06520696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MILC application
Description: Eligible Hispanic participants in their third trimester will be recruited for the study. Intervention group will receive standard WIC services plus the MILC application. Standard WIC support includes on-site lactation consultation, bilingual peer counseling, weekly peer support meetings, free breast pump, and enhanced food package for BF mothers. If a participant has trouble with breastfeeding, she will be referred to a home-visiting breastfeeding peer counselor in the area. Participants will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months along with demonstrating breastfeeding via MILC app. Participants will send in 1 BF video per month using the MILC app to verify continued BF and fill out monthly self-report to verify EBF. Participants in the incentive group will receive escalating monthly points as incentives for every additional month of continued BF and EBF.
Study NCT06520696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants in the control group will receive care as usual with standard breastfeeding services from the WIC program and will be asked to participate in the periodic follow-up assessments at 1, 3 and 6 months. Participants in the control group can receive financial compensation for the completion of assessments. This is necessary to maximize retention and adherence to the monthly assessment schedule, provide comparable remuneration as the incentive group, and minimize demoralization of control group participants following treatment assignment. All participants are informed of the differential group procedures during the randomization consent process. In addition to the follow-up assessment, control group will also complete a monthly self-report on BF status (both for EBF and any BF). For attention control purposes in this group, participants will be referred to a mobile app for tracking the baby's milestones called Baby Connect.
Study NCT05650463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
Study NCT04808791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase I inhibitor.
Study NCT04808791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Oxaliplatin is classified as an alkylating agent.
Study NCT04808791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102 (Trifluridine/Tipiracil)
Description: Trifluridine/Tipiracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as an antimetabolite/pyrimidine analog; antimetabolite/thymidine phosphorylase inhibitor
Study NCT05210088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypoxia, intermittent
Description: The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.
Study NCT05210088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypoxia, intermittent
Description: The device used to generate the intermittent hypoxia stimulus is a gas mixer used in current clinical practice and research (Altitrainer®, SMTEC S.A. Switzerland). The hypoxic stimulus will be obtained by having the subject inhale a gas mixture enriched in nitrogen by means of a mask, in variable proportion according to the desired degree of hypoxia.~Hypoxic conditioning will be performed in three one-hour sessions per week, performed non-consecutively, for 8 weeks. The hypoxic stimulus will be intermittent, and each session will consist of 7 cycles of 5 minutes of hypoxia alternating with 3 minutes of normoxia (FiO2 = 21%). The subjects will be installed in a semi-recumbent position, at rest in a quiet environment.~For hypoxic exposure, the inspired fraction of oxygen (FiO2) will be set individually to achieve the targeted level of desaturation (Pulse Oxygen Saturation, SpO2) continuously monitored.
Study NCT05210088 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxia
Description: The normoxic stimulus will be obtained by having the subjects inhale via a face mask a normoxic gas mixture with a fixed FiO2 of 21%, delivered by the gas mixing device (Altitrainer®, SMTEC S.A. Switzerland).
Study NCT05498935 — intervention group
Intervention type: OTHER
Intervention: CPB time
Description: Cardiopulmonary bypass time
Study NCT04483141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Abbey Pain Scale
Description: Hetero-assessment of pain
Study NCT05511376 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AURICULAR VAGUS NERVE STIMULATION
Description: For 4 weeks With the Vagustim device, in Biphasic, Frequency 10 Hz, Modulation mode, the pulse width of 300 μs, where the participants feel comfortable, the current intensity is kept constant for 30 minutes / 3 days/week. It will be applied as bilateral VSS from the tragus and turbinate parts of the ear.
Study NCT05511376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: For 4 weeks, Protein intake to 30% of total daily calories or 1-1.2 g/kg Personal nutrition program created for ideal body weight (by BMI values for age)
Study NCT05511376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EXERCISE
Description: Exercise: Moderate Resistance Exercise Protocol (60 min 3 days a week )+ 30 min/day as aerobic exercise ( 5 days a week)
Study NCT05787275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic positioning
Description: Traditional medical treatment plus diaphragmatic strengthening exercises through patient self-positioning in prone on elbows then do diaphragmatic breathing 10-15 min ,twice/day, 7days/ weak
Study NCT04099355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 5mg Cap
Description: 1 QAM and 2 QHS PO 14 days
Study NCT04099355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 5mg Cap
Description: 1 QAM and 2 QHS PO 14 days
Study NCT04099355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-active comparator
Description: 1 QAM and 2 QHS PO 14 days
Study NCT04099355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-active comparator
Description: 1 QAM and 2 QHS PO 14 days
Study NCT05787275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: incentive spirometer
Description: Traditional medical treatment plus diaphragmatic strengthening exercises through using of incentive spirometer 10-15 min ,twice/day, 7days/ weak
Study NCT05787275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Traditional medical treatment
Study NCT06120387 — intervention group
Intervention type: PROCEDURE
Intervention: Radical surgery
Description: Radical nephroureterectomy
Study NCT05111197 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRT
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy are treated with SRT, in addition to their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.~A maximum of 3 Brain metastases treatable in stereotactic radiotherapy will be included among these hypermetabolic lesions.~Each lesion is treated with a total dose of 24 Gy delivered in 3 fractions of 8 Gy (isodose surface).
Study NCT05111197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
Study NCT05111197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Patients with a maximum of 5 residual hypermetabolic lesions observed on 18F- FDG PET / CT after a minimum of 6 months of immunotherapy continue their anti-PD-1 or anti-PD-L1 immunotherapy as it was administered before randomization in the trial, according to the standards.
Study NCT06120387 — intervention group
Intervention type: RADIATION
Intervention: Kidney sparing surgery+Postoperative radiotheray
Description: Kidney sparing surgery+Postoperative radiotheray
Study NCT04898595 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discontinuation of CRRT
Description: Discontinuation of CRRT will be guided by an algorithm based on patient current condition.
Study NCT05713526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth service
Description: Researchers will send educational materials (video and e-brochures) about childhood vaccinations to the participants' mobile phones at regular intervals, answer their questions over the phone and send reminder messages before the vaccination appointment.
Study NCT05876663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping will be applied for 6 weeks and it will be changed with new one after every two days
Study NCT05075018 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Individuals' musculoskeletal problems will be evaluated with the Cornell Musculoskeletal Disorder Questionnaire, quality of life, physical activity, Nottingham Health Profile physical activity International Physical Activity Questionnaire, endurance stabilizer device, functional exercise capacity 1 minute sit and stand test, shortness of breath using the Modified Borg Scale. Measurements will be made only once.
Study NCT05876663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy protocol
Description: Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks.
Study NCT05876663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy protocol
Description: Stretching exercise for pectoralis minor and major:10 sets and 2 sessions per day for 6 weeks.~Strengthening of Rhomboids and Trapezius muscle: 10 sets and 2 sessions per day for 6 weeks.~Deep Breathing: 10 rep and 2 sessions per day for 6 weeks.
Study NCT05353010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus 5mg (1 mg \* 5 capsules)
Study NCT05353010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A001(Tegoprazan)
Description: IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)
Study NCT05353010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A001(Tegoprazan) + Tacrolimus
Description: IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)
Study NCT04706286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D759, D150
Description: CKD-501 0.5 mg 1T, D759 100 mg 1T and D150 1000 mg 1T, single oral administration under fed condition
Study NCT04706286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 0.5/100/1000 mg
Description: CKD-393 0.5/100/1000 mg 1T, single oral administration under fed condition
Study NCT04935424 — intervention group
Intervention type: DEVICE
Intervention: ApolloVue® S100 Image System (Apollo Medical Optics)
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for both experimental group and control group. The ApolloVue S100 image system is a high resolution OCT imaging system that provide real-time visualization of human skin tissue microstructure. The system provides cellular level, two-dimensional, cross-sectional (B-scan) and en face (E-scan) that can assist clinical diagnosis.The system is also equipped with imaging guiding system that could assist in position scanning skin area.
Study NCT06337253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine plus amodiaquine
Description: Seasonal Malaria Chemoprevention with SPAQ has not been trialed or introduced in Malawi yet. This intervention trial is different from others because of the location and because, traditionally, a full round of SMC with SPAQ that involves between 3-5 cycles is administered. Our trial is the first one that will only distribute one cycle of SMC with SPAQ. The data collected during the 42 days after SMC distribution will be used to estimate the medicines chemoprevention effectiveness at preventing malaria in children aged 3-59 months. This data, together with the resistance markers data will then be fed into a dynamical model that collaborators at Imperial College London have developed that will predic the potential impact of upscaling SMC in similar geographies.